Edoxaban tosylate monohydrate, a white to pale yellow crystalline powder, is described as practically insoluble in water under the descriptive solubility terms of Ph. Eur. 5.11. This aqueous solubility limitation conditions every oral solid dosage form. In direct compression film-coated tablets intended for once-daily oral anticoagulant therapy, the API is usually micronised before blending to reduce segregation risk in low-dose formulations. The target dose strengths of 15 mg, 30 mg, and 60 mg edoxaban per tablet require that the micronised fraction be distributed homogeneously across a larger excipient mass. Particle size control is commonly performed by laser diffraction according to USP <429> and Ph. Eur. 2.9.31, with the D90 specification established in the manufacturer’s drug master file rather than in a public monograph. For low-dose direct compression blends, a D90 below 20 µm is a typical industrial target, because larger crystals can segregate during bin transfer and tablet press feeding. However, excessive micronisation below 2 µm may increase cohesiveness and reduce flowability; the resulting blend can exhibit compressibility index values above 30% when tested per USP <1174> and Ph. Eur. 2.9.36. On a rotary tablet press, pre-compression force and main compression force must be established by compaction-simulator studies because the tosylate salt can adhere to punch faces. Published data for edoxaban tosylate-specific compaction profiles is limited, so formulation scientists typically evaluate sticking and picking using instrumented tablet press trials with chromium nitride or diamond-like carbon coated tooling. Tablet cores are compressed to a breaking force measured by USP <1217>, while friability is controlled according to USP <1216> with a limit of not more than 1.0% weight loss after 100 revolutions. Dissolution is evaluated using USP <711> apparatus II with paddle speed 50 rpm in a medium selected to discriminate between formulations; because edoxaban tosylate solubility is pH-dependent, media such as 0.01 N hydrochloric acid or pH 4.5 acetate buffer are often screened. Uniformity of dosage units is evaluated per USP <905> and Ph. Eur. 2.9.40 with an acceptance value of not more than 15.0 for the release specification. Residual solvent levels are controlled under USP <467> and ICH Q3C, and elemental impurities are controlled under USP <232>/233 and ICH Q3D.

What Processing Parameters Govern Low-Dose Capsule Filling with Edoxaban Tosylate?

Hard capsule presentations for edoxaban tosylate are typically developed as an alternative to film-coated tablets when dose flexibility or blinding in clinical studies is required. The low mass fraction of API in a size 3 or size 4 capsule makes ordered mixing with a coarse carrier such as lactose monohydrate or mannitol the most robust approach. Carrier particle size is selected between 80 µm and 150 µm D50 to provide surface roughness for adhesion of micronised drug particles; published data for edoxaban tosylate-specific ordered mix stability is limited. Powder blend uniformity is monitored at multiple time points during bin storage and capsule hopper residence to detect segregation. Capsule fill weight is controlled on a dosator or dosing-disc encapsulation machine using fill weight acceptance criteria derived from the product specification, and content uniformity is assessed by USP <905> and Ph. Eur. 2.9.40. Disintegration testing is performed according to USP <701> and Ph. Eur. 2.9.1 in 0.1 N hydrochloric acid at 37±2 °C; however, disintegration alone does not predict bioequivalence because edoxaban tosylate is practically insoluble in water and dissolution is rate-limiting. Hard gelatin capsules with equilibrium moisture between 13% and 16% w/w may be unsuitable for moisture-sensitive formulations; HPMC capsules with lower moisture content between 3% and 7% w/w are often evaluated. If gelatin cross-linking is observed during accelerated stability at 40 °C and 75% relative humidity, dissolution failures can occur due to pellicle formation; the use of protease enzymes in the dissolution medium per USP <711> is then required for diagnosis. On production-scale encapsulation, powder bridging in the hopper is a recurrent failure mode when the blend is over-lubricated with magnesium stearate; blending time is therefore limited to fewer than 5 min after the lubricant is added, and the use of a low-shear diffusion mixer at container fill levels below 60% avoids shear-induced charge build-up. Electrostatic adhesion to plastic capsule-handling parts is controlled by maintaining relative humidity between 40% and 50% in the encapsulation suite.

Roller compaction is introduced when direct compression blends of micronised edoxaban tosylate exhibit flow failure or low bulk density in the feed frame of a rotary tablet press. The dry granulation route uses a horizontal roller compactor with a gap setting and roll force selected to achieve ribbon solid fraction between 0.60 and 0.75. Ribbons below this range produce granules that are too friable and generate fines; ribbons above this range reduce tablet tensile strength because of work hardening. The ribbon is milled through an oscillating granulator with a screen aperture between 0.8 mm and 1.25 mm, and the resulting granules are blended with extragranular disintegrant before compression. Particle size distribution of granules is measured by sieve analysis according to Ph. Eur. 2.9.38 and USP <786>. Published data for edoxaban tosylate-specific roll compaction parameters is limited; therefore, a compactability index and brittle fracture index are generated using a compaction simulator before transferring the process to production scale.

Granule-Based Oral Delivery Requires Tight Moisture Specification Limits

For single-dose sachet and granule formulations, edoxaban tosylate is granulated to improve flow, reduce dust generation, and enable weight-based filling. When wet granulation is used, the binder solution is typically an aqueous or hydroalcoholic solution of hydroxypropyl cellulose or povidone; however, the practically insoluble nature of edoxaban tosylate does not preclude wetting-related degradation, and the final granule moisture must be controlled. Granule moisture is measured by loss on drying per USP <731> or Karl Fischer per USP <921>, with acceptance criteria established from stability data. At moisture levels above 2.0% w/w, powder flow and chemical stability can be compromised; a final drying endpoint below 2.0% is therefore common for moisture-sensitive oral granules. The dried granules are passed through a 1.0 mm screen, and oversized material is rejected unless remilling is validated. Granule flow is assessed by Ph. Eur. 2.9.36 and USP <1174>, with the goal of a compressibility index below 25%. For film-coated granules or sachet filling, particle attrition during pneumatic transfer is a critical source of fines; the granule fraction below 75 µm is monitored because excessive fines can cause segregation and dose inaccuracy.

Injectable Solution Chemistry and Filter Compatibility

In parenteral development, edoxaban tosylate is constrained by the same aqueous solubility limitation that governs oral formulation. Aqueous solubility screening is performed by the shake-flask method at 37 °C across pH 1.2 to 8.0; because edoxaban tosylate is practically insoluble in water, simple pH adjustment may not achieve a target concentration sufficient for intravenous administration. Co-solvent systems containing propylene glycol or polyethylene glycol are evaluated, as are inclusion complexes with hydroxypropyl-β-cyclodextrin; published data for edoxaban tosylate-specific solubilisation efficiency is limited. For any injectable formulation, tonicity is adjusted to 290 mOsm/kg with sodium chloride or mannitol and confirmed by USP <785>. The pH of the finished solution is controlled within a narrow range because precipitation can occur upon dilution with blood or infusion fluids; a dilution test in 0.9% sodium chloride injection and 5% dextrose injection is part of the preformulation screen. Filter compatibility is studied with sterilising-grade 0.22 µm polyethersulfone or polyvinylidene fluoride membranes under constant pressure. Adsorptive loss of a low-concentration edoxaban salt to the membrane can be significant; recovery below 90% in the first 50 mL of filtered solution indicates membrane saturation or incompatibility. The finished solution is tested for subvisible and visible particulates according to USP <788> and Ph. Eur. 2.9.19, with acceptance criteria for small-volume injections of not more than 6000 particles per container at ≥10 µm and not more than 600 particles per container at ≥25 µm. Sterility assurance follows aseptic processing under 21 CFR 211.113, with sterility testing per USP <71> and Ph. Eur. 2.6.1. Bacterial endotoxins are controlled according to USP <85> and Ph. Eur. 2.6.14, with the limit calculated from the maximum human dose and route of administration. Terminal steam sterilisation is not assumed; if terminal sterilisation is proposed, thermal degradation kinetics must be established by forced degradation per ICH Q1A(R2).

When Edoxaban Tosylate Is Lyophilised for Parenteral Use

For lyophilised presentations, the pre-lyophilisation solution is filtered through 0.22 µm sterilising filters and filled into Type I borosilicate glass vials. A bulking agent such as mannitol or glycine is included to provide cake structure; crystallisation of mannitol during the freezing step can produce a mechanically stable cake at primary drying shelf temperatures below the collapse temperature. The collapse temperature of the formulation is measured by freeze-drying microscopy; published collapse temperature data for edoxaban tosylate formulations is limited, so representative placebo and active formulations are characterised for each new composition. Primary drying is performed at a shelf temperature that maintains product temperature below the collapse temperature and chamber pressure between 50 mTorr and 200 mTorr. Residual moisture after lyophilisation is measured by Karl Fischer per USP <921> Method Ic and is generally controlled at not more than 1.0% for a dry cake. The reconstituted solution is tested for particulate matter according to USP <788>, osmolality per USP <785>, pH, and visual clarity. The sealed vials are subjected to container closure integrity testing using dye ingress or vacuum decay; method validation follows USP <1207>. Because edoxaban tosylate is a salt, the choice of counterion and pH can affect cake appearance and reconstitution time; published data for this specific configuration is limited.

In the absence of a licensed oral liquid, extemporaneous dispersion of edoxaban tosylate granules in water for enteral feeding tubes is not recommended without stability verification; published data on dose recovery through polyurethane feeding tubes is limited.